Literature DB >> 7211914

Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years.

Y S Haider, W C Roberts.   

Abstract

The degrees of cross-sectional area luminal narrowing by atherosclerotic plaques of each 5 mm long segment of each of the four major (right, left main, left anterior descending and left circumflex) epicardial coronary arteries in 22 necropsy patients (age 16 to 37 years, 21 women) with systemic lupus erythematosus (SLE) was determined, and the findings were compared to those in 13 control subjects. Of 623 coronary segments (5 mm long) in the patients with SLE, 80 (13 percent) were narrowed 76 to 100 percent (controls = 0 of 431 segments); 125 (20 percent), 51 to 75 percent (controls = 6 percent); 273 (44 percent), 26 to 50 percent (controls = 31 percent). Of the 22 patients with SLE, 10 had one or more of the four major coronary arteries narrowed 76 to 100 percent in cross-sectional area, and 12 patients had lesser degrees of narrowing similar to that in the 13 control subjects. The 10 patients with SLE and severe coronary narrowing compared to the 12 patients with SLE and no severe (greater than 75 percent) coronary narrowing had significantly higher (1) mean values of total serum cholesterol (382 versus 290 mg/dl), (2) mean systolic/diastolic systemic arterial pressures (175/119 versus 151/93 mm Hg), (3) frequencies of mitral valvular disease (seven of 10 patients versus none of 12 patients) and (4) frequencies of pericardial adhesions (seven of 10 patients versus three of 12 patients).

Entities:  

Mesh:

Year:  1981        PMID: 7211914     DOI: 10.1016/0002-9343(81)90532-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  29 in total

1.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

2.  William Clifford Roberts, MD: an interview by W. Bruce Fye, MD.

Authors:  William C Roberts; W Bruce Fye
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-07

Review 3.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

4.  Recurrent very late stent thrombosis in a systemic lupus erythematous patient.

Authors:  Dong-Yob Lee; Jong-Pil Park; Sung-Jun Ko; Shin-Eun Lee; Sung-Hee Jhon; Ji-Hyun Lim; Jay-Young Rhew
Journal:  Korean Circ J       Date:  2012-02-27       Impact factor: 3.243

5.  Transfer of renovascular hypertension and coronary heart disease by lymphoid cells from SLE-prone mice.

Authors:  L Hang; P M Stephen-Larson; J P Henry; F J Dixon
Journal:  Am J Pathol       Date:  1984-04       Impact factor: 4.307

Review 6.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

7.  A rare case of acute myocardial infarction with a non-specific symptom in a young female with systemic lupus erythematosus.

Authors:  Tomo Komaki; Shin-Ichiro Miura; Kouki Gondo; Ayumi Nakamura; Amane Ike; Akira Matsunaga; Keijiro Saku
Journal:  J Cardiol Cases       Date:  2017-06-09

8.  Calorie restriction prevents the occlusive coronary vascular disease of autoimmune (NZW x BXSB)F1 mice.

Authors:  H Mizutani; R W Engelman; K Kinjoh; Y Kurata; S Ikehara; Y Matsuzawa; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

Review 9.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Arterial thrombotic manifestations in young women associated with the lupus anticoagulant.

Authors:  E J Ter Borg; J Van der Meer; J T De Wolf; M H Van Leeuwen; C G Kallenberg
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.